The Obesity Drug Game of $ 870 million of Eli Lilly could turn the market, will it be the next $ 1T stock?

Indianapolis, in -Le Lilly (NYSE: LLY), an important player in the rapid weight weight loss drug market, has signed an important license agreement with the Swedish Biotechnology Company Camurus to improve the way in which their medications for obesity are delivered. The agreement gives Lilly access to Camurus fluidcrycrycrycrycrycrycrycrrystal®, which allows medications to be slowly released in the body, which potentially reduces the frequency with which patients should take them.

Lilly will pay Camurus $ 290 million in advance, and the agreement could grow to almost $ 870 million with payments of milestones and royalties. The measure aims to solve one of the greatest complaints about current weight loss injections such as Lilly zero: the need for a weekly dose and the risk of recovering weight if patients stop taking the medication.

What is special for the new technology?

Camurus fluidcrycrycrycrystal technology converts injectable medications into a gel -shaped deposit in the body, slowly releasing the medication over time. This could allow weight loss treatments to be taken monthly instead of weekly, which makes them much more convenient and potentially improve patient adhesion.

Lilly plans to try this technology with four of its GLP-1 medicines, including Zepbound and Mounjaro, which are already box office hits in the obesity and diabetes space.

Less pain, more gain for patients and profits

• Best patient experience: Less injections might mean that more people will stay with treatment, which leads to better long -term results.

• Stronger competitive position: This movement helps Lilly stay at the forefront of rival Novo Nordisk and other companies that run to improve the convenience of weight loss medications.

• Sales increase: If more people start or remain in Lilly’s drugs because they are easier to use, that could mean thousands of millions in future revenues.

In the first quarter of 2025, Eli Lilly reported a 45% leap in revenues year after year, reaching $ 12.7 billion. Zepbound and Mounjaro together represent a growing part of that total.

Other innovations in the pipeline

Lilly is also progressing in other types of drugs to lose weight. He recently reported solid results for a pill version of his GLP-1 medicine, called Orforglipron. Instead of an injection, this version is taken once a day orally, another option that could attract more users.

Beyond weight loss, Lilly is developing treatments for Alzheimer’s disease, eczema, cancer and chronic pain. New medications such as Kisunla (Alzheimer), Ebglyss (Eczema) and Jaypirca (blood cancer) are expected to become important income drivers.

What could go wrong?

• The competition is growing rapidly. Companies like Amgen and Novo Nordisk are also developing prolonged action or drug pills GLP-1.

• Regulatory risks. The new rules about obesity drugs, or the costs of costs of insurers and governments, could affect prices or availability.

• Manufacturing pressure. The demand is raising, and any delay in production could stop the growth of sales.

Should I consider buying Lly shares?

With a strong impulse in your main business, bold investments in new delivery technologies and a growing channeling of promising drugs, Eli Lilly remains a main contender in biotechnology. The Camurus agreement is a forward movement that could help you stay at the top of the weight loss market and expand its advantage in this billionaire space.

Eli Lilly not only pursues income through its weight loss franchise: it is sitting fundamentals for long -term domain in multiple therapeutic fronts. With late -stage candidates in Alzheimer’s, oncology, chronic pain and a pipe that moves towards gene therapy, the company is positioning less as a drug manufacturer with a star product and more as a platform player in the areas of high -margin diseases. For investors, the story is not exaggerated: its scale, execution and a pipe built to absorb future winds against.

Also read: Eli Lilly Stock increases since the new weight loss pill offers 8% fall in body weight